Abstract Background Cardiovascular Magnetic resonance (CMR) with the late gadolinium
enhancement (LGE) technique allows the detection of myocardial fibrosis in Hypertrophic …

Please note: Mr. Baruah, Mr. Hoyt, Mr. Cabe, Mr. Oglesby, Drs. Estrada, Milner, and Feldman
have received at least partial salary support from The Clayton Foundation for Research …

Aims Regional myocardial fibrosis detected by magnetic resonance imaging (MRI) using
late enhancement (LE) indicates an unfavorable prognosis. We investigated in a prospective …

Abstract Background Sphingolipid deposition in Fabry disease causes left ventricular (LV)
hypertrophy, of which the accurate assessment is essential. Cardiovascular magnetic …

Background: Fabry cardiomyopathy is characterized by left ventricular hypertrophy,
myocardial fibrosis, arrhythmia, and premature death. Treatment with migalastat, an oral …

Editor: In a retrospective study in the January 2020 issue of Radiology, Dr Hanneman and
colleagues reported cardiac MRI findings in 90 patients with Fabry disease (FD)(1). Left …

Fabry disease (FD) is a rare lysosomal storage disorder resulting in myocardial sphingolipid
accumulation which is detectable by cardiovascular magnetic resonance as low native T1 …

Background: In prehypertrophic Fabry disease, low myocardial T1 values, reflecting
sphingolipid storage, are associated with early structural and ECG changes. The …

The present study evaluated the evolution of cardiac morphology, function, and late
enhancement as a noninvasive marker of myocardial fibrosis, and their inter-relation during …

Background High‐sensitivity troponin (hs‐TNT), a biomarker of myocardial damage, might
be useful for assessing fibrosis in Fabry cardiomyopathy. We performed a prospective …